Aim: To examine the effect of synthetic muscone on the expression of CYP1A2 and CYP3A4 enzymes in human liver L02 cells and in the liver tissue of Kunming mice. Methods: The L02 hepatic cell line was used to study the effect of low (10-4 μmol/L), middle (10-3 μmol/L), and high concentrations (10-2 μmol/L) of muscone on the expression of CYP1A2 and CYP3A4 enzymes. In addition, the cytochrome P450 (CYP) expression was investigated in Kunming mice after the administration of 10 mg/kg (low), 50 mg/kg (middle), and 100 mg/kg (high) dose of muscone for 6 days. A mixture of phenobarbital (30 mg/kg) and β-napthoflavone (80 mg/kg) was used as positive control and the effects of the compounds on CYP expression were investigated at the end of 6- and 12-day periods. Results: Muscone induced the expression of CYP1A2 (middle and low concentrations) and of CYP3A4 (high concentration) enzymes in L02 cells. In vivo, administration of muscone in Kunming mice revealed significant weight reduction at the end of 6- and 12-day periods (middle and high doses, respectively), compared to the control group (p < 0.05). Liver toxicity scores indicated that the liver injuries in the positive control and high doses of muscone group were significantly higher in the 6- and 12-day periods, compared to those in the blank control group (p < 0.05). Furthermore, muscone induced CYP1A2 and CYP3A11 expressions in Kunming mice at the middle dose and all doses during the 12-day period as demonstrated by immunoblotting experiments. A low dose of mucone induced the CYP enzyme expression more rapidly, whereas a high dose of muscone caused the longest inductive effect. The results were confirmed by immunohistochemistry experiments and real-time PCR studies, where similar patterns of muscone-mediated inductive effects were noted. Conclusions: Muscone induces CYP1A2 and CYP3A4 expression in liver cells in vitro and in vivo. In addition, it exhibits liver toxicity in Kunming mice at concentrations higher than 50 mg/kg. The CYP-inductive effect that is caused by muscone encompasses a 6- to 12-day period of activity after drug administration as demonstrated by follow-up in vivo studies.

Keywords:
Muscone, CYP1A2, CYP3A4, CPY3A11
1.
Feng W, You Y, Yong H, Li G, Gu D: Histological observation of Chinese forest musk deer (moschus berezovskii flerov) musk glands (in Chinese). Zool J 1981:13-15.
2.
Hawkins TH: Musk and the musk deer. Nature 1950;166:262.
3.
Li D, Chen B, Zhang L, Gaur U, Ma T, Jie H, Zhao G, Wu N, Xu Z, Xu H, Yao Y, Lian T, Fan X, Yang D, Yang M, Zhu Q, Satkoski Trask J: The musk chemical composition and microbiota of Chinese forest musk deer males. Sci Rep 2016;6:18975.
4.
Liang QQ, Zhang M, Zhou Q, Shi Q, Wang YJ: Muscone protects vertebral end-plate degeneration by antiinflammatory property. Clin Orthop Relat Res 2010;468:1600-1610.
5.
Wu Q, Li H, Wu Y, Shen W, Zeng L, Cheng H, He L: Protective effects of muscone on ischemia-reperfusion injury in cardiac myocytes. J Ethnopharmacol 2011;138:34-39.
6.
Wei G, Chen DF, Lai XP, Liu DH, Deng RD, Zhou JH, Zhang SX, Li YW, Li H, Zhang QD: Muscone exerts neuroprotection in an experimental model of stroke via inhibition of the fas pathway. Nat Prod Commun 2012;7:1069-1074.
7.
Lin DL, Chang HC, Huang SH: Characterization of allegedly musk-containing medicinal products in Taiwan. J Forensic Sci 2004;49:1187-1193.
8.
Taneja V, Siddiqui HH, Arora RB: Studies on the anti-inflammatory activity of Moschus moschiferus (musk) and its possible mode of action. Indian J Physiol Pharmacol 1973;17:241-247.
9.
Wang X, Meng H, Chen P, Yang N, Lu X, Wang ZM, Gao W, Zhou N, Zhang M, Xu Z, Chen B, Tao Z, Wang L, Yang Z, Zhu T: Beneficial effects of muscone on cardiac remodeling in a mouse model of myocardial infarction. Int J Mol Med 2014;34:103-111.
10.
Oh SM, Yeon JD, Nam HY, Park DK, Cho MH, Chung KH: Acute and subacute toxicity studies of l-muscone in rats. Korean J Toxicol 1997;15:207-213.
11.
Tanaka E, Kurata N, Kohno M, Yoshida T, Kuroiwa Y: Induction of cytochrome P-450 and related drug-oxidizing activities in muscone (3-methylcyclopentadecanone)-treated rats. Biochem Pharmacol 1987;36:4263-4267.
12.
Tanaka E, Funae Y, Imaoka S, Misawa S: Characterization of liver microsomal cytochrome P450 from rats treated with muscone (3-methylcyclopentadecanone). Biochem Pharmacol 1991;41:472-473.
13.
Guengerich FP: Cytochrome p450 and chemical toxicology. Chem Res Toxicol 2008;21:70-83.
14.
Androutsopoulos VP, Tsatsakis AM, Spandidos DA: Cytochrome P450 CYP1A1: wider roles in cancer progression and prevention. BMC Cancer 2009;9:187.
15.
Nebert DW, Dalton TP: The role of cytochrome P450 enzymes in endogenous signalling pathways and environmental carcinogenesis. Nat Rev Cancer 2006;6:947-960.
16.
Callejo R, Corr MJ, Yang M, Wang M, Cordes DB, Slawin AM, O'Hagan D: Fluorinated musk fragrances: the CF2 group as a conformational bias influencing the odour of civetone and (R)-muscone. Chemistry 2016;22:8137-8151.
17.
Shirasu M, Yoshikawa K, Takai Y, Nakashima A, Takeuchi H, Sakano H, Touhara K: Olfactory receptor and neural pathway responsible for highly selective sensing of musk odors. Neuron 2014;81:165-178.
18.
Ma Y, Li Y, Li X, Wu Y: Anti-inflammatory effects of 4-methylcyclopentadecanone on edema models in mice. Int J Mol Sci 2013;14:23980-23992.
19.
Gerets HH, Tilmant K, Gerin B, Chanteux H, Depelchin BO, Dhalluin S, Atienzar FA: Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins. Cell Biol Toxicol 2012;28:69-87.
20.
Zaravinos A, Lambrou GI, Boulalas I, Delakas D, Spandidos DA: Identification of common differentially expressed genes in urinary bladder cancer. PLoS One 2011;6:e18135.
21.
Liang X, Xu G, Gao Q, Tao X: LKB1 expression reverses the tumorigenicity of L02 cells. Oncol Rep 2016;36:1055-1061.
22.
Zeng T, Zhang CL, Song FY, Zhao XL, Xie KQ: Garlic oil alleviated ethanol-induced fat accumulation via modulation of SREBP-1, PPAR-α, and CYP2E1. Food Chem Toxicol 2012;50:485-491.
23.
Shang H, Wei H, Yue B, Xu P, Huang H: Microsatellite analysis in two populations of Kunming mice. Lab Anim 2009;43:34-40.
24.
Inaba T, Nebert DW, Burchell B, Watkins PB, Goldstein JA, Bertilsson L, Tucker GT: Pharmacogenetics in clinical pharmacology and toxicology. Can J Physiol Pharmacol 1995;73:331-338.
25.
Gibson GG, Plant NJ, Swales KE, Ayrton A, El-Sankary W: Receptor-dependent transcriptional activation of cytochrome P4503A genes: induction mechanisms, species differences and interindividual variation in man. Xenobiotica 2002;32:165-206.
26.
Willson TM, Kliewer SA: PXR, CAR and drug metabolism. Nat Rev Drug Discov 2002;1:259-266.
27.
Amacher DE: The effects of cytochrome P450 induction by xenobiotics on endobiotic metabolism in pre-clinical safety studies. Toxicol Mech Methods 2010;20:159-166.
28.
Zanger UM, Schwab M: Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 2013;138:103-141.
29.
Lee SJ, Goldstein JA: Comparison of CYP3A4 and CYP3A5: the effects of cytochrome b5 and NADPH-cytochrome P450 reductase on testosterone hydroxylation activities. Drug Metab Pharmacokinet 2012;27:663-667.
30.
Guengerich FP, Martin MV, Beaune PH, Kremers P, Wolff T, Waxman DJ: Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J Biol Chem 1986;261:5051-5060.
31.
Oh SM, Yeon JD, Nam HY, Park DK, Cho MH, Chung KH: Acute and subacute toxicity of l-muscone in rats. Korean J Toxicol 1997;13:435-447.
32.
You AS, Kweon OK, Sung HJ, Kwak HI, Fang MZ, Park DK, Chung KH, Yoon HI, Cho MH: Acute and subacute toxicity of l-muscone in beagle dogs. Korean J Toxicol 1997;13:449-460.
33.
Wanwimolruk S, Phopin K, Prachayasittikul V: Cytochrome P450 enzyme mediated herbal drug interactions (Part 2). Excli J 2014;13:869-896.
34.
He BX, Shi L, Qiu J, Zeng XH, Zhao SJ: The effect of CYP3A4*1G allele on the pharmacokinetics of atorvastatin in Chinese Han patients with coronary heart disease. J Clin Pharmacol 2014;54:462-467.
35.
Villeneuve JP, Pichette V: Cytochrome P450 and liver diseases. Curr Drug Metab 2004;5:273-282.
36.
Tan BS, Tiong KH, Muruhadas A, Randhawa N, Choo HL, Bradshaw TD, Stevens MF, Leong CO: CYP2S1 and CYP2W1 mediate 2-(3,4-dimethoxyphenyl)-5-fluorobenzothiazole (GW-610, NSC 721648) sensitivity in breast and colorectal cancer cells. Mol Cancer Ther 2011;10:1982-1992.
37.
Mcginty D, Letizia CS, Api AM: Fragrance material review on 3-methyl-1-cyclopentadecanone. Food Chem Toxicol 2011;49(suppl 2):S120-S125.
38.
Belsito D, Bickers D, Bruze M, Calow P, Dagli ML, Fryer AD, Greim H, Miyachi Y, Saurat JH, Sipes IG: A toxicological and dermatological assessment of macrocyclic ketones when used as fragrance ingredients: the RIFM expert panel. Food Chem Toxicol 2011;49(suppl 2):S126-S141.
39.
Wu Q, Li H, Leng Y, Deng H, Cheng H, Shen W: Determination of muscone in rats plasma following oral administration of artificial musk: using of combined headspace gas chromatography-mass spectrometry. J Spectrosc 2014;2014:1-5.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.